Amye J. Tevaarwerk, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Amye Tevaarwerk, MD, obtained her medical degree from Washington University School of Medicine and completed an internship and residency in internal medicine at Barnes Jewish Hospital. Prior to entering clinical fellowship, she worked as a hospitalist for a year at Barnes Jewish Hospital in St. Louis. She completed a medical oncology fellowship at the University of Wisconsin. Her academic area of interest is breast oncology, with a focus on new drug development and women’s health issues as they relate to cancer survivorship. Dr. Tevaarwerk is a member of the UW Health Breast Center and part of Breast Disease-Oriented Working Group, through which multiple clinical trials in breast cancer are helping to find better treatments for those with cancer.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
University of Wisconsin Hospital and Clinics, Madison, WI
Barnes-Jewish Hospital, St. Louis, MO
Barnes-Jewish Hospital, St. Louis, MO
Washington University, St. Louis, MO, 2002
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Dr. Tevaarwerk’s research interests include breast oncology and Phase I clinical trials.
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G .
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res. 2016 Jun 1;22(11):2659-67
[PubMed ID: 27026198]
Wisinski KB Xu W Tevaarwerk AJ Saha S Kim K Traynor A Dietrich L Hegeman R Patel D Blank J Harter J Burkard ME .
Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer. 2016 Mar 31;
[PubMed ID: 27133732]
Neuman HB Steffens NM Jacobson N Tevaarwerk A Anderson B Wilke LG Greenberg CC .
Oncologists' Perspectives of Their Roles and Responsibilities During Multi-disciplinary Breast Cancer Follow-Up. Ann Surg Oncol. 2016 Mar;23(3):708-14
[PubMed ID: 26474556]
Tevaarwerk AJ Lee JW Terhaar A Sesto ME Smith ML Cleeland CS Fisch MJ .
Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer. 2016 Feb 1;122(3):438-46
[PubMed ID: 26687819]
Mirrielees JA Breckheimer KR White TA Denure DA Schroeder MM Gaines ME Wilke LG Tevaarwerk AJ .
Breast Cancer Survivor Advocacy at a University Hospital: Development of a Peer Support Program with Evaluation by Patients, Advocates, and Clinicians. J Cancer Educ. 2015 Oct 19;
[PubMed ID: 26477478]
Wisinski KB Cantu CA Eickhoff J Osterby K Tevaarwerk AJ Heideman J Liu G Wilding G Johnston S Kolesar JM .
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm. 2015 Jun 1;72(11):958-65
[PubMed ID: 25987691]
Ehsani S Strigel RM Pettke E Wilke L Tevaarwerk AJ DeMartini WB Wisinski KB .
Screening magnetic resonance imaging recommendations and outcomes in patients at high risk for breast cancer. Breast J. 2015 May-Jun;21(3):246-53
[PubMed ID: 25789917]
Andreason M Zhang C Onitilo AA Engel J Ledesma WM Ridolfi K Kim K Charlson JC Wisinski KB Tevaarwerk AJ .
Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result. J Community Support Oncol. 2015 May;13(5):195-201
[PubMed ID: 26029936]
Donohue S Sesto ME Hahn DL Buhr KA Jacobs EA Sosman JM Andreason MJ Wiegmann DA Tevaarwerk AJ .
Evaluating primary care providers' views on survivorship care plans generated by an electronic health record system. J Oncol Pract. 2015 May;11(3):e329-35
[PubMed ID: 25804989]
LoConte NK Razak AR Ivy P Tevaarwerk A Leverence R Kolesar J Siu L Lubner SJ Mulkerin DL Schelman WR Deming DA Holen KD Carmichael L Eickhoff J Liu G .
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs. 2015 Feb;33(1):169-76
[PubMed ID: 25318436]
Tevaarwerk AJ Wang M Zhao F Fetting JH Cella D Wagner LI Martino S Ingle JN Sparano JA Solin LJ Wood WC Robert NJ .
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014 Dec 10;32(35):3948-58
[PubMed ID: 25349302]
Burkard ME Wisinski KB Njiaju UO Donohue S Hegeman R Stella A Mansky P Shah V Goggins T Qamar R Dietrich L Kim K Traynor AM Tevaarwerk AJ .
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer. 2014 Jun;14(3):205-11
[PubMed ID: 24342730]
Rocque GB Wisinski KB Buhr KA Froeschner JL Jones N Donohue S Wiegmann D Sesto ME Tevaarwerk AJ .
Development and evaluation of a survey to assess survivor knowledge change after survivorship care plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer). J Cancer Educ. 2014 Jun;29(2):270-7
[PubMed ID: 24343267]
Tevaarwerk AJ Wisinski KB Buhr KA Njiaju UO Tun M Donohue S Sekhon N Yen T Wiegmann DA Sesto ME .
Leveraging electronic health record systems to create and provide electronic cancer survivorship care plans: a pilot study. J Oncol Pract. 2014 May;10(3):e150-9
[PubMed ID: 24520142]
Zasadil LM Andersen KA Yeum D Rocque GB Wilke LG Tevaarwerk AJ Raines RT Burkard ME Weaver BA .
Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014 Mar 26;6(229):229ra43
[PubMed ID: 24670687]
Tevaarwerk AJ Gray RJ Schneider BP Smith ML Wagner LI Fetting JH Davidson N Goldstein LJ Miller KD Sparano JA .
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013 Mar 15;119(6):1140-8
[PubMed ID: 23065954]
Sesto ME Faatin M Wang S Tevaarwerk AJ Wiegmann DA .
Employment and retirement status of older cancer survivors compared to non-cancer siblings. Work. 2013;46(4):445-53
[PubMed ID: 24004736]
Tevaarwerk A Burkard ME Wisinski KB Shafer MM Davis LA Gogineni J Crone E Hansen KE .
Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast Cancer Res Treat. 2012 Jul;134(1):245-51
[PubMed ID: 22350731]
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G .
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
Rocque G Onitilo A Engel J Pettke E Boshoven A Kim K Rishi S Waack B Wisinski KB Tevaarwerk A Burkard ME .
Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Res Treat. 2012 Jan;131(2):713-21
[PubMed ID: 22065290]